Floatz logo

Bortezomib

Acute Lymphoblastic Leukemia

Instituto do Cancer do Estado de São PauloSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
65/ 100

Competitive context

252 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →